¹Department of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, London, UK

Correspondence: J Acheson, Department of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Tel: +4420 7837 3611 X 3382; Fax: +4420 7676 2041; E-mail: james.acheson@moorfields.nhs.uk

Received 4 September 2003; Accepted 4 September 2003.

Abstract

Optic nerve sheath decompression (ONSD) maintains a role in the management of visual loss complicating papilloedema in selected patients primarily with idiopathic intracranial hypertension. The evidence base for this intervention is reviewed and audit data on visual outcomes for patients with acute, chronic, and atrophic forms of papilloedema are contrasted. Optic canal decompression has a role in the management of compressive optic neuropathies complicating mass lesions arising from paranasal sinuses and intracranially and can be achieved by transethmoidal, transbasal, and open craniotomy routes. The evidence base supporting this intervention in traumatic optic neuropathy and in primary bone disease causing canal stenosis (in particular fibrous dysplasia) is reviewed where the indications are more controversial.